Clinic Contacts
Opportunities
User Login

T2D Pediatric Working Group Friday, April 11, 2025

 

T2D Pediatric Work Group meeting minutes, 4/11/25 

Participants: Ori Odugbesan, Tim Bol, Mary Pat Gallagher, Leena Mamilly, Tosssaporn Seeherunvong, Sean DeLacey, Monica Bianco, Heba El Ayash, Jeniece Ilkowitz, Talia Hitt, Shideh Majidi, Lily Chao, Risa Wolf, Michelle Coulter, Ryan Brady, Rohan Henry, Anna Cymbaluk, Liz Mann, Andrea Huber, Jessica Johnson, Shylaja Srinivasan, Kimberly McNamara, Jessica Schmitt, Mili Vakharia, Carla Demeterco-Berggren 

 

 Agenda   Notes   Next steps  
 
  • Introductions were made by Ori and new members of the Work Group were introduced.   
   

 
Questions and discussions   
  • Drs. Monica Bianco and Sean DeLacey, Lurie Children’s Hospital, presented the work that their center is doing.  
  • Tim provided an update on data mapped centers. 
  • Dr. Liz Mann provided an update on the T2D abstract and discussed what to call this group: “Pediatrics T2D Registry” for now. 
  
Next Meeting 
  • Due to a scheduling conflict, the May Meeting will be rescheduled. A doodle form will be sent out to determine the ideal time and date for a replacement meeting.
  
Link to Recording  https://us02web.zoom.us/rec/share/aog74Qe-bqjG87NlRGCk-0qFiKAqP8em6k8J8jtM8hcNvt8Omy2HfzXfZ_esuTo9.6Ix1ilUlAwSKkuDD?startTime=1744383751000 

 Passcode: #ZKi1=N9 

  

 

T1DX-QI

T1DX-QI

This Post Has One Comment

  1. I wanted to follow up on my understanding of when to initially treat kids with new-onset diabetes as “as T1D,” even if we suspect T2D. After the call, I reviewed the statements from the ADA and ISPAD for the last few years.

    I saw that my recollection of treating “as if T1D” if there is “marked post-prandial hyperglycemia” was outdated.

    However, I also saw that while the ADA algorithm Figure says it’s okay to treat with metformin and basal insulin even if there are ketones (as long as no DKA or HHS), the text is a little more nuanced, and at times contradictory, and the ISPAD recommendations are slightly different.

    I asked Megan Kelsey and Amy Shah about the differences between the ADA and PES guidance. For anyone going to the PES Meeting next month, we may discuss this in more depth in person at the Diabetes SIG Meeting.

    I look forward to seeing the data that we collect as a collaborative to see if the no rapid-acting insulin approach (at times even when transitioning to subcutaneous insulin) can be as successful in all of our centers as it has been in theirs.

    Thanks,
    Mary Pat

Leave a Reply